Plasma Supply Falling Behind Demand: Kristopher Jonas Sounds the Alarm
Kristopher Jonas, CEO/President of Proesis Biologics, posted on LinkedIn:
”You know what’s scary?
The growing gap between how much plasma-derived medicine the world needs and how much plasma we’re actually collecting.
Global demand for immunoglobulins (IG) continues to climb 6–8% each year. And that’s not even factoring in underutilization in low to middle-income countries.
Fractionators are bringing new manufacturing capacity online across the U.S. and Europe.
But all that capacity still depends on one thing – human plasma – and the supply side isn’t keeping pace.
That’s where independent collectors come in.
We’re the flexible link in the chain, able to expand quickly, reach new donor communities, and help ensure the growing global infrastructure doesn’t sit idle waiting for plasma.
Not spooky. Just real.
And it’s why what we’re building at Proesis Bio matters.”
Keep up with Hemostasis Today.
-
Oct 6, 2026, 02:59Preventing Hospital Associated Venous Thromboembolism – Thrombosis Canada
-
Oct 6, 2026, 02:42Treatment of Iron Deficiency With and Without Anemia – American Society of Hematology
-
Oct 6, 2026, 02:36Mouna Sassi: When Clinical and Laboratory Perspectives Meet in Thrombosis Care
-
Oct 6, 2026, 02:35Lucia Stefanini: Platelet Dysfunction and Oxidized Phospholipids in MASLD
-
Oct 6, 2026, 02:18Pablo Corral: Association of Lp(a) With Coronary Atherosclerosis and CV Events
-
Oct 5, 2026, 22:55Steve Humphreys: A Big Thank You to BSHT for Providing Me With a Recent Skills Exchange Award
-
Oct 5, 2026, 22:52William McKeown: Great to Be in Istanbul for the Opening of the EHC 2026
-
Oct 5, 2026, 22:48Laura Quintas Lorenzo: A New Approach to Healthcare for von Willebrand Disease at EHC 2026
-
Oct 5, 2026, 22:46Anas Zayad: Pleased to Share Our New Review on Thrombosis in SCD and Beta Thalassemia